The Correlation Between Tumor Angiogenesis and the Effect of Radiation Therapy in Cervical Cancer Patients

The recruitment status of this study is unknown because the information has not been verified recently.
Verified June 2004 by National Taiwan University Hospital.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
National Taiwan University Hospital
ClinicalTrials.gov Identifier:
NCT00155077
First received: September 9, 2005
Last updated: October 19, 2005
Last verified: June 2004
  Purpose

Carcinoma of the uterine cervix is a serious health problem. Cervical cancer is the most common malignant neoplasm of women in Taiwan. There were 2,720 new cases of invasive carcinoma of the cervix and 971 deaths from the disease in 2000. Cervical cancer is indeed is an important disease in Taiwan.

The primary therapies for cervical cancer are surgery, radiotherapy or chemoradiotherapy. Several clinical trials have showed that an improvement in time to progression and survival for patients given chemoradiotherapy compared with radiotherapy alone. Chemoradiotherapy is now regarded as standard modality to treat the locally advanced (stage IIB–IVA) or high-risk early-stage cervical cancer. However, some of the cervical cancer patients still failed to response to the treatment of cervical cancer or relapsed for completion of treatment.

Angiogenesis plays an important role in the pathogenesis of cancer. Recent studies have related angiogenesis to cancer growth and metastasis Ultrasonography has been used in the gynecologic field for decades. The previous studies of our team have shown that incremental angiogenesis could be demonstrated in the tumorigenesis of ovarian, endometrial malignancies, and cervical caner. Besides, other growth factors such as vascular endothelial growth factor (VEGF), and IL-6 have also been reported to correlate with the angiogenesis and the prognosis of cervical cancer. It seems that tumor angiogenesis could be utilized as a good marker to survey the severity of disease and prognosis of early-staged cervical cancer patients.

There is no good method or marker which could be utilized to monitor the response of radiotherapy and evaluate the prognosis of cervical cancer patients with advanced stages. So we would like to propose this proposal to focus on the tumor angiogenesis in cervical cancer patients with advanced stages. There are several purposes in this study. First, we will evaluate the kinetic changes of tumor angiogenesis in cervical cancer patients who receive radiotherapy or concurrent chemoradiotherapy. Second, we will evaluate that if the tumor angiogenesis could be a marker to monitor the response of radiotherapy or chemoradiotherapy in cervical cancer patients. The relation between tumor angiogenesis and radiotherapy will be explored and clarified by this study. The comprehensive role of tumor angiogenesis in cervical cancer will be elucidated by the results of this study.


Condition
Cervical Cancer

Study Type: Observational
Study Design: Observational Model: Defined Population
Primary Purpose: Screening
Time Perspective: Longitudinal
Official Title: The Correlation Between Tumor Angiogenesis and the Effect of Radiation Therapy in Cervical Cancer Patients

Resource links provided by NLM:


Further study details as provided by National Taiwan University Hospital:

Estimated Enrollment: 200
Study Start Date: June 2004
Estimated Study Completion Date: June 2009
  Show Detailed Description

  Eligibility

Ages Eligible for Study:   18 Years to 85 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

- cervical cancer patients receiving radiotherapy or chemo-radiotherapy

Exclusion Criteria:

-

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00155077

Contacts
Contact: Chao-Yuan Huang, M.D. 886-2-2312-3456 ext 7635 cyh@ha.mc.ntu.edu.tw

Locations
Taiwan
National Taiwan University Hospital Recruiting
Taipei, Taiwan, 100
Contact: Chao-Yuan Huang, M.D.    886-2-2312-3456 ext 7635    cyh@ha.mc.ntu.edu.tw   
Sponsors and Collaborators
National Taiwan University Hospital
Investigators
Principal Investigator: Chao-Yuan Huang, M.D. National Taiwan University Hospital
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00155077     History of Changes
Other Study ID Numbers: 9361700771
Study First Received: September 9, 2005
Last Updated: October 19, 2005
Health Authority: Taiwan: Department of Health

Keywords provided by National Taiwan University Hospital:
cervical cancer, chemoradiotherapy, angiogenesis

Additional relevant MeSH terms:
Uterine Cervical Neoplasms
Uterine Neoplasms
Genital Neoplasms, Female
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Uterine Cervical Diseases
Uterine Diseases
Genital Diseases, Female

ClinicalTrials.gov processed this record on July 22, 2014